American Heart Association

Comorbid Conditions and Health-Related Quality of Life in Ambulatory Heart Failure Patients

Contributor: Ike Chinyere

Comorbid Conditions and Health-Related Quality of Life in Ambulatory Heart Failure Patients
REVIVAL (Registry Evaluation of Vital Information for VADs in Ambulatory Life)

Study Link: Comorbid Conditions and Health-Related Quality of Life in Ambulatory Heart Failure Patients

Increased Mortality in Patients with Respiratory Failure Before or After Durable LVAD Implantation

Contributor: Sadaf Sharfaei

Clinical Implications of Respiratory Failure in Patients Receiving Durable Left Ventricular Assist Devices for End-Stage Heart Failure

Study Link: Clinical Implications of Respiratory Failure in Patients Receiving Durable Left Ventricular Assist Devices for End-Stage Heart Failure

VITALITY-HFpEF: Designed to test the hypothesis that vericiguat may improve physical functioning in patients with HFpEF

Contributor: Emily Cendrowski

VITALITY-HFPEF is a trial underway which will evaluate the efficacy of vericiguat in HFpEF patients by using the KCCQ-PLS (Kansas City Cardiomyopathy Questionnaire Physical Limitation Score) as a primary endpoint. The choice of this primary endpoint will make it the first HF trial utilizing a quality of life, patient-reported outcome (PRO) as a primary endpoint. There remains a need for medications which improve mortality and functional status for patients with HFpEF. An ongoing area of research involves the cyclic guanosine monophosphate (cGMP) pathway.

NT-proBNP is more predictive of unfavorable outcomes in HFpEF in the absence of AFib

Contributor: Martin Chacon

Does an increased NT-proBNP in patients with atrial fibrillation (AF) and HFpEF correspond to a higher risk for worse outcomes? Kristensen et al suggest increased NTproBNP levels do not show the same correlation with poor outcomes in patients with AF compared with those without AF. NT-proBNP is increased in AF patients independently from heart failure, therefore, its capacity to predict cardiovascular death or hospitalizations in HFpEF may be diminished.

Visual Abstract: Cardiac Troponin I and Cardiac Events in HFpEF Patients

Contributor: Ike Chinyere

Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction

Study Link: Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction